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been highlighted as one method of improving patient outcomes. Recent technologic advances have meant that introducing
MR-only planning to the clinic is becoming a reality, with several specialist radiation therapy clinics using this technique
for treatment.As such, substantial efforts are beingmade to introduce this technique intowide-spread clinical implementation.
A systematic review of publications investigating the clinical implementation of pelvic MR-only radiation therapy treatment
planningwas undertaken following the PreferredReporting Items for SystematicReviews andMeta-Analyses guidelines. The
Medline, Embase, Scopus, Science Direct, Cumulative Index to Nursing and Allied Health Literature, and Web of Science
databases were searched (timespan: all years to January 2, 2019). Twenty-six articles met the inclusion criteria. The studies
were grouped into the following categories: (1) MR acquisition and synthetic computed tomography generation verification,
(2) MR distortion quantification and phantom development, (3) clinical validation of patient treatment positioning in anMR-
only workflow, and (4) MR-only commissioning processes. Key conclusions from this review are (1) MR-only planning has
been implemented clinically for prostate cancer treatments; (2) a substantial amount of work remains to translate MR-only
planning into widespread clinical implementation for all pelvic sites; (3) MR scanner distortions are no longer a barrier to
MR-only planning, but theymust bemanaged appropriately; (4)MR-onlyebased patient positioningverification showsprom-
ise, but limited evidence is reported in the literature and further investigation is required; and (5) a number of MR-only
commissioning processes have been reported, which can aid centers as they undertake local commissioning; however,
this needs to be formalized in guidance from national bodies. 2019 The Authors. Published by Elsevier Inc. This is an open
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Bird et al. International Journal of Radiation Oncology  Biology  Physics480Introduction Appendix E1 (available online at https://doi.org/10.1016/One of greatest challenges remaining in radiation therapy is
improving the accuracy of treatment volume delineations.1
Further reducing the uncertainty in delineation could lead
to improved patient outcomes by reducing treatment vol-
umes, allowing a reduction in treatment-related toxic-
ities,2,3 or reducing the risk of geographic misses, thereby
improving local control and potentially overall survival
rates. The use of magnetic resonance imaging (MRI) scans
alone for radiation therapy treatment planning (magnetic
resonance [MR]-only planning) has been highlighted as one
method of potentially improving target volume delineation
accuracy4-6; this is due to the improved soft tissue contrast
of MRI compared with computed tomography (CT) and the
potential to use the other benefits of MRI, such as func-
tional imaging.5
Recent technological advances have meant that intro-
ducing MR-only planning to the clinic is becoming a re-
ality.5,7 Hardware and software developments have
improved the geometric distortion inherent within MR
images to levels that are acceptable for radiation therapy
treatment planning,8 and substantial progress has been
made in acquiring electron density information from MRI
data alone through synthetic CT generation methods.4,9 The
field of synthetic CT generation has been reviewed,4,9 and
commercial solutions are available, including several
prostate solutions and, recently released, a solution for the
whole pelvis.10-12 Consequently, MR-only treatments are
being conducted by specialist radiation therapy clinics and
over time are likely to move to more widespread clinical
implementation.
This systematic review assesses the literature surround-
ing the clinical implementation of pelvic MR-only radiation
therapy treatment planning with the aim of detailing and
discussing the breadth of work that has been undertaken.
This review considers only work that has been published in
relation to MR-only planning for pelvic external beam ra-
diation therapy.Methods and materials
A systematic review of publications investigating the
clinical implementation of pelvic MR-only external beam
radiation therapy treatment planning was performed
using the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses guidelines.13 The Medline,
Embase, Scopus, Science Direct, Cumulative Index to
Nursing and Allied Health Literature, and Web of Sci-
ence databases were searched with a time span of all
years to January 2, 2019 (for Medline and Embase, this
corresponded to “Week 3 December 2018” and “Week 52
2018,” respectively) using the search protocols inj.ijrobp.2019.06.2530).
Articles were included that referred to “MR-only” or
“synthetic-CT” and “radiotherapy” or synonyms of these
terms in their title or abstract. These deliberately broad
search criteria were used to minimize the risk of relevant
studies not being identified. The search results for each
database were combined, and duplicates were removed.
The remaining results were screened from their titles for
eligibility. Primary screening included only search results
that were related to the use of MRI in radiation therapy for
cancer treatment. Secondary screening included only arti-
cles related to the clinical implementation of MR-only
external beam radiation therapy treatment planning for
pelvic cancer sites. Articles focusing on the general use of
MRI in radiation therapy, MRI in brachytherapy, synthetic
CT model generation techniques, target volume delineation
using MRI, MR image registration, positron emission to-
mography/MRI in radiation therapy, MRI safety, MR-only
contouring, and MR-only fiducial marker identification
were excluded. Articles regarding synthetic CT model
generation techniques were specifically excluded because
they were appraised recently in the literature within 2 re-
view articles4,9 and because this review is focused on the
clinical implementation, rather than the technique devel-
opment, aspect of MR-only planning. Conference pro-
ceedings were excluded because of their large number and
variable information provision, which made their inclusion
unbeneficial. A backward citation search of the remaining
eligible studies was undertaken. The included studies were
categorized according to their focus. For each category, key
findings from each study were included in a data table.Results
The database search results can be seen in Figure 1. The
combined database search resulted in 2024 records, with
1066 records remaining after duplicate removal. After pri-
mary screening, 535 records remained. After secondary
screening, 71 studies remained. After further review, 49
studies were removed (44 conference abstracts and 5
studies that did not meet the eligibility criteria). Twenty-
two studies remained, to which the citation search added
4 studies; thus, 26 studies were included in this systematic
review. The categories and number of excluded articles can
be seen in Table 1.
Included studies were organized into one or more of the
following categories for review: (1) MR acquisition and
synthetic CT generation verification, (2) MR distortion
quantification and phantom development, (3) clinical vali-
dation of patient treatment positioning in an MR-only
workflow, and (4) MR-only commissioning processes.
These 4 categories will be discussed in more detail.
Records identified through database 
search:
2024
Records after duplicates removed:
1066
Records screened for MR in RT: 
1066
Full text article assessed for eligibility:
71
Studies included:
22
Records excluded:
531
Records excluded:
49
(44 conference abstracts)
Records identified through citation 
search:
4
Records screened for clinical 
implementation of MR-only: 
535
Records excluded:
464
Fig. 1. Flowchart of the systematic review process, including the number of studies included in this review.
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verification
The systematic review identified 9 studies investigating MR
acquisition or synthetic CT generation verification.6,14-21 A
key summary of study results can be found in Table 2. All
studies reported results relating to prostate cancer treatment
planning. Studies reporting synthetic CT dosimetric accu-
racy findings were included when they were validating
previously reported synthetic CT generation models as part
of clinical implementation, rather than as part of the
development of a synthetic CT model.
Tenhunen et al,14 Kerkmeijer et al,15 Christiansen et al,16
and Tyagi et al17 reported treating patients using an MR-
only pathway, with the number of patients treated ranging
from 125 to 1.14,16 Tenhunen et al14 also reported the MR-
only patient cohort’s initial clinical response in terms of
early response PSA and acute toxicity follow-up.
Persson et al,6 Tenhunen et al,14 and Tyagi et al17 re-
ported their experiences of prospectively acquiring MR
data for MR-only treatment planning in terms of their MR
scan success rates and the issues that prevented successful
scanning. In the case of Persson et al,6 case, this was from amulticenter research-only study for commissioning pur-
poses, whereas other experiences14,17 resulted from treating
their first MR-only patients. Wyatt et al20 reported MR scan
success rates from retrospectively assessed MR data,
whereas Christiansen et al16 reported synthetic CT gener-
ation success rate but did not discuss issues regarding MR
acquisition. In describing their clinical workflow for MR-
only planning, Tyagi et al17 also reported a time savings
when using an MR-only versus CT-MRIebased workflow.
Previous studies6,16,18-21 reported validating the dosi-
metric accuracy of their respectively chosen synthetic CT
solution in a clinical environment, as required for
commissioning MR-only planning.MR distortion quantification and phantom
development
The systematic review identified 13 studies investigating
MR distortion quantification methods or phantom devel-
opment.18,19,22-32 A key summary of study results can be
found in Table 3.
Table 1 Categories and number of articles excluded from
this review after primary, secondary, and tertiary screening
Reasons for exclusion
No. of
articles
Primary screening
Not related to cancer treatment 65
Not related to radiation therapy cancer treatment 301
Not related to the use of MRI in radiation therapy
cancer treatment
165
Total 531
Secondary screening
General use of MRI 115
Other site synthetic CT generation technique 98
Brain synthetic CT generation technique 65
Brachytherapy, Gamma knife 48
Prostate synthetic CT generation technique 43
MR delineation 33
MR image registration 12
Proton or ion synthetic CT generation technique 12
Other 10
MR-only contouring 7
MR-only fiducial marker identification 7
PET-MRI 7
UTE synthetic CT generation techniques 5
MR safety 2
Total 464
Tertiary screening
Conference abstracts 44
MR-only review articles 3
Synthetic CT model development studies 2
Total 49
Abbreviations: CT Z computed tomography; MR Z magnetic
resonance; MRI Z magnetic resonance imaging; PET Z positron
emission tomography; UTE Z ultrashort echo time.
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measuring geometric distortions or end-to-end testing the
MR-only pathway. Huang et al,23 Price et al,22 and Walker
et al24 developed large field of view (FoV) phantoms for
assessing system (Bo) distortions and characterized their
respective MR scanner distortions. Price et al22 and Huang
et al23 assessed the setup reproducibility of their phantoms
using CT scan testing methods, and Walker et al24 assessed
the effects of a continuous moving-table acquisition method
on measured distortions with 0, 1.1, and 2 mm/s table
speeds.
Sun et al25 and Cunningham et al26 developed
anthropomorphic pelvic-shaped phantoms for measuring
system and patient-induced susceptibility distortions or
end-to-end testing of the MR-only pathway. Both phan-
tom designs were based on prostate patient anatomic
sizes. The phantom of Sun et al25 had 2 designs for end-
to-end testing or geometric distortion assessment. Cun-
ningham et al26 designed the phantom so that it could
simulate patient bladder and rectal filling for end-to-end
testing, including dosimetric verification of treatment
plans.Some authors18,19,27-29 investigated the effects of MR
scanner distortions on patient treatments by applying
measured or simulated distortions to patient treatment
plans. Kemppainen et al19 and Gustafsson et al27 measured
system-induced geometric distortions using large FoV
phantoms for 15 and 10 patients, respectively. Tyagi et al,18
Kemppainen et al,19 and Glide-Hurst et al28 measured
patient-induced susceptibility geometric distortions for 20,
4, and 9 patients, respectively, with Glide-Hurst et al28
assessing distortions for different patient bladder-filling
states and scanner magnet strengths. Adjeiwaah et al29
assessed the effects of MRI scanner-measured system and
simulated patient-induced susceptibility distortions for 17
patients.
Wyatt et al30 evaluated the repeatability and setup
sensitivity of the commercially available GRADE (Spec-
tronics Medical AB, Helsingborg, Sweden), large-FoV
distortion phantom. The distortion measurement repeat-
ability was assessed for interscanning and intrascanning
session variability. The setup sensitivity of the phantom was
investigated by deliberately scanning the phantom with a 1-
mm offset and 1 degree of rotation and assessing distortion
variations.
Torfeh et al31 and Price et al32 characterized their MR
scanner system and gradient nonlinearity distortions
respectively over large FoVs as required for MR-only
planning. Torfeh et al31 assessed the effects of manufac-
turer 2-dimensional and 3-dimensional distortion correction
algorithms on clinically used radiation therapy sequences.
Price et al32 characterized and minimized inherent 2-
dimensional and 3-dimensional large-FoV gradient
nonlinearity distortions using postprocessing techniques.Clinical validation of patient treatment positioning
in an MR-only workflow
The systematic review identified 3 articles investigating the
clinical validation of patient treatment positioning verifi-
cation.18,33,34 A key summary of study results can be found
in Table 4. These studies have been included because they
report patient treatment positioning verification results for
previously reported MR-only treatment synthetic CT
models as part of clinical implementation.
Tyagi et al,18 Kemppainen et al,33 and Korhonen et al34
evaluated the accuracy of synthetic CTs as digitally
reconstructed radiograph (DRR) reference images for
treatment positional verification using orthogonal planar
images,18,33,34 cone beam CT (CBCT), or both.18,34
Tyagi et al18 and Kemppainen et al33 investigated the
PhilipsMRCAT synthetic CT solution. The DRR analysis by
Kemppainen et al33 included interobserver and intraobserver
variability, separating the variability into systematic and
random error contributions and comparing the total geo-
metric accuracy to a reference of 2 mm error from CT to MR
registration. The CBCT analysis by Tyagi et al18 was based
Table 2 Summary of the key results from the MR acquisition and synthetic CT generation verification studies*
Author Year
sCT
technique
No.
patients
in study
MR
acquisitions
MR scanner
and magnet
strength
No. of
patients
treated
with MR
only
sCT
success
rate (%) Other key information
Christiansen
et al16
2017 Philips -
MRCAT
30 T1 mDIXON Philips
Ingenia, 1.5 T
1 97
(29/30)
1. MR synthetic CT generation failed in 1
case, reason unknown
2. Dosimetric accuracy for
gamma analysis of 2%/
2 mm - median 100% in
all structures
3. Rectal gas found to be
main contributor to
dosimetric errors
Kemppainen
et al19
2017 Philips -
MRCAT
5 T1 mDIXON Philips
Ingenia, 1.5 T
X X Only prostate patient data
from study included
1. Mean dosimetric accuracy (prostate pa-
tients) for 2%/2 mm and 1%/1 mm
gamma analysis of 100% and 99.2%,
respectively, within PTV
2. Mean relative dose difference of 0.7% in
PTV and <1.2% in OARs
Maspero
et al21
2017 Philips -
MRCAT
14 T1 mDIXON Philips
Ingenia, 3 T
X X Mean relative dose difference between CT and
sCT found to be 0.3% within the CTV and
0.04% within the whole body
Persson
et al6
2017 Spectronics
Medical -
MRIPlanner
170 T2 SPACE GE Discovery
(3 T), GE
Signa (3 T),
Siemens
Area (1.5 T),
Siemens
Skyra (3 T)
X 85
(145/170)
1. Patient MR acquisition issues (no. of
patients): distortion correction turned off
(12), whole body not included in FoV (4),
insufficient superior-inferior coverage
(2), hip prosthesis patients (2), extreme
rectum change between CT and MR (1)
2. Mean dosimetric deviations of less than
0.3% for all targets and organs
3. Multicentered (4 centers) study found
insignificant differences found between
range of treatment techniques, planning
systems, prescribed doses, calculation
models and target volumes
Tyagi
et al17
2017 Philips -
MRCAT
48 T1 mDIXON Philips
Ingenia, 3 T
42 87.5
(42/48)
1. Patient MR acquisition issues (no. of
patients): hip prosthesis patients (4), large
patient exceeded MRCAT size limitations
(2)
2. Dedicated software used ed for contour-
ing workflow. MR sequence blurring
affected 2-dimensional DRR fiducial
marker identification in 2 patient cases
3. MRCAT failure modes: (i) presence of
hip prosthesis, (ii) significant bone dis-
ease in pelvis, (iii) significant discrep-
ancies from the bone model boundary
conditions, and (iv) patient size exceeds
50 cm left-right or 30 cm anteroposterior
4. Time saving of w15 minutes using MR-
only simulation compared with CT-MR
simulation, further 15-minute savings
estimated in the future if logistic chal-
lenges resolved
Tyagi
et al18
2017 Philips -
MRCAT
25 T1 mDIXON Philips
Ingenia, 3 T
X X Mean relative dose difference between sCT and
CT <0.5%
Wyatt et al20 2017 Dowling
et al40
21 T2 SPACE Philips
Magneto
Espree, 1.5 T
X 54
(21/37)
Retrospective data
collection
1. Patient data set exclusions (no. of pa-
tients): required patient body outside of
MR FoV (13), hip prostheses (2), gross
patient motion (1)
2. Dosimetric accuracy for 2%/2 mm
gamma analysis: mean 98.9%, minimum
97.6%, and maximum 99.5% in all
structures
(continued on next page)
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Table 2 (continued )
Author Year
sCT
technique
No.
patients
in study
MR
acquisitions
MR scanner
and magnet
strength
No. of
patients
treated
with MR
only
sCT
success
rate (%) Other key information
Kerkmeijer
et al15
2018 Philips -
MRCAT
Not
known
T1 mDIXON Philips
(unknown)
Yes,
number
unknown
Not
known
1. Inclusion criteria: fiducial markers pre-
sent in prostate
2. Exclusion criteria: hip prostheses and
contraindications for MRI
Tenhunen
et al14
2018 Korhonen
et al39
250 T1 mDIXON GE Optima,
1.5 T
125 92
(184/200)
1. Patient MR acquisition issues (no. of
patients): gold markers not identifiable
(8), hip prosthesis related distortions (5),
obesity (2), motion (1)
2. CT vs MR-only patient treatment out-
comes: PSA and acute toxicities results
showed no significant differences be-
tween pathways
3. Noted lack of support of MR-only
workflow from technical software,
including planning systems
Abbreviations: CT Z computed tomography; DRR Z digitally reconstructed radiograph; MR Z magnetic resonance; MRI Z magnetic resonance
imaging; PTV Z planning target volume; sCT Z synthetic computed tomography.
* “No. of patients in study” refers to the total number of patients recruited for MR-only investigations, “MR-only treated patients” refers to the number
of patients planned and treated using the MR-only technique, and “sCT success rate” refers to the percentage of patients for whom a useable sCT was
generated.
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CBCT scans were included for registration per patient.
The DRR analysis by Korhonen34 included interobserver
variability and investigated the use of both the synthetic CT
and MR images as reference images for CBCT registration.
CBCT registrations were undertaken using ELEKTA x-ray
volume imaging (XVI) software (Elekta, Stockholm,
Sweden) for 5 patients, with 10 CBCT scans for each pa-
tient (50 CBCT registrations per reference modality).
MR-only commissioning processes
The systematic review identified 6 articles investigating
MR-only commissioning processes.15,21,35-38 A key sum-
mary of study results can be found in Table 5.
Kerkmeijer et al,15 Kapanen et al,35 and Kim et al36
reported experiences related to commissioning an MR-
only pathway. Kerkmeijer et al15 and Kapanen et al35
used their experiences of commissioning an MR-only
pathway and an MR simulator, respectively, to present
recommendations for clinically commissioning an MR-
only pathway, including proposing quality-assurance
testing and associated levels of acceptability with indi-
vidual pathway components. Kim et al36 used a failure
mode and effects analysis methodology to systematically
assess the risksdand their frequency, severity, and
detectabilitydof an MR-only planning pathway
compared with CT-MR based pathway. This analysis
included mapping the respective elements required for an
MR-only pathway, their risks, and associated mitigation
strategies.
Maspero et al21 and Korsholm et al37 reported synthetic
CT accuracy assessment methodologies. Maspero et al21quantified the confounding factors in MR-only dose
calculation accuracy assessments for patients with pros-
tate cancer, including interscan differences (setup and
positioning differences, MR-related geometric inaccuracy,
and registration errors) and synthetic CT generation and
electron density conversion errors. Korsholm et al37
developed a statistical approach to evaluating the signif-
icance of errors introduced by MR-only planning
compared with CT-based planning, with the criterion that
95% of patients should have an uncertainty in dose
calculation within 2% of the CT dose for relevant
structures.
Palmer et al38 developed and validated a quality assur-
ance procedure for assessing synthetic CT clinical feasi-
bility using kV-CBCT, where CBCT scans were used to
recalculate the synthetic CT treatment plan as a check of its
dose calculation accuracy.
Discussion
A wide range of findings are reported in this systematic
review. Several key findings are seen in the literature, and
these are highlighted here before being discussed in more
detail later. These findings are (1) MR-only planning has
been clinically implemented for prostate cancer treatments;
(2) a substantial amount of work remains to translate MR-
only planning into widespread clinical implementation for
all pelvic sites; (3) MR scanner distortions are no longer a
barrier to MR-only planning, but they must be managed
appropriately; (4) MR-only based patient positioning veri-
fication shows promise, but limited evidence is reported in
the literature and further investigation is required; and (5) a
number of MR-only commissioning processes have been
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commissioning, but this needs to be formalized in guidance
from national bodies.
As highlighted, in 4 studies patients with prostate cancer
were treated using an MR-only planning solution, showing
that clinical implementation is achievable.14-17 It is inter-
esting to note that all commissioning work identified in this
review was also focused on prostate treatments. This is a
natural starting point for pelvic MR-only planning because
other pelvic sites (rectum, bladder, anus, gynecological)
have a number of additional challenges associated with
them, including differences in male and female anatomy,
significantly larger treatment volumes, and nonefiducial-
marker-based 3-dimensional imaging requirements, which
makes their implementation more complex. It is important
to note that the majority of work discussed is translatable to
other cancer sites; however, it is clear that a significant
amount of work remains to widen the implementation of
MR-only planning to all pelvic cancer treatments.
This review identified 3 key areas that were investigated
for clinical implementation purposes: MR acquisition and
synthetic CT generation verification, MR distortion quan-
tification and phantom development, and clinical validation
of patient treatment positioning in an MR-only workflow.
In each, no major barriers to implementation were found,
and a number of publications reported commissioning
methodologies that will benefit the wider community by
providing guidance for local centers to use within their own
MR-only clinical commissioning.
The first step to implementing an MR-only pathway is
ensuring that sufficient and suitable MR data acquisition is
achieved. A high success rate of acquiring MRI that is
usable for synthetic CT generation is key to the widespread
implementation of MR-only techniques because this will
limit the need for additional CT scans. Persson et al,6
Tenhunen et al,14 and Tyagi et al17 all described their
success rates in prospective studies and categorized the
identified issues related to scanning. The similar scan
success rates (85%-92%) suggest that this is an achievable
percentage in any center, particularly considering the
multicenter study by Persson et al.6 The differences in
success rate can be explained by the variations in study
design. The exclusion criteria of Persson et al6 included
patients with hip prostheses and operator error as valid
reasons for an unsuccessful MRI scan, whereas Tenhunen
et al14 and Tyagi et al17 had no exclusion criteria. Wyatt
et al20 also analyzed their successful scanning rate (54%);
however, their rate was severely affected by a lack of
scanning guidance for MR operators caused by the retro-
spective design of the study. However, the study does still
provide useful information regarding common issues with
MR acquisition in this context. Centers should ensure that
training from experienced personnel is provided for MR
scan operators and consider methods to identify errors at
the point of acquisition to ensure MR scan success. Ten-
hunen et al14 and Tyagi et al17 identified several patient and
hardware- and software-related issues that also preventedsuccessful MR-only planning and therefore required a
percentage of patients to revert to a CT-MRIebased
pathway. Although further development of MR-only solu-
tions could lead to a reduction in patients requiring an
additional CT scan, provisions should still be made for CT-
based planning to occur. In addition, these studies do not
discuss patients who have contraindications to MRI and
therefore will always require a CT-only pathway.
Christiansen et al,16 did not report MR acquisition
success, but they described their synthetic CT generation
failure rate, finding that 3% (1 of 30) of synthetic CT ex-
aminations failed to generate using the Philips MRCAT
solution. This was considered to be due to the software’s
“sanity” check ability to prevent obviously erroneous
synthetic CT generation, although the exact cause was not
established. This finding highlights that synthetic CT
generation methods require input data to follow clearly
defined criteria to be successful, and it is a beneficial
feature that the Philips MRCAT safeguards against inap-
propriate data, defined as including large patient sizes,
large disease sites (300 mm or greater scan lengths), and
hip prostheses.17,19 It is of note that Tyagi et al17 did not
have any similar issues. This result could have been due to
a systematic difference in pathway, such as Tyagi’s use of a
specific mold for each patient to achieve a more robust
patient position, or a non-systematic, patient-specific,
issue. This is another example of the variety of errors
associated with an MR-only planning pathway that require
careful assessment.
For acquired MR data to be clinical usable, their dosi-
metric accuracy needs to be quantified robustly as within
acceptable limits. Dosimetric accuracy of prostate synthetic
CT solutions was investigated by the majority of studies and
considered to be clinically acceptable in all cases.6,16,18-21
The similar results of these studies, despite significant dif-
ferences in study design including various synthetic CT
generation methods, shows that the dosimetric accuracy of
synthetic CT techniques is broadly reproducible across a
wide range of clinical systems and techniques, including
multiple commercial options available for prostates.10,11 The
presented studies also provide a suitable blueprint for centers
wishing to begin clinical implementation of MR-only plan-
ning themselves regarding dosimetric accuracy assessment.
These studies progress by first assessing dosimetric accuracy
through research-only studies, followed by end-to end
pathway testing and eventual implementation only when the
local results provided sufficient confidence that theMR-only
planning was sufficiently dosimetrically accurate to be used
without CT for assurance.
In addition to dosimetric accuracy, another key criterion
of useable MR data for MR-only treatment planning is that
it be geometrically accurate. To be sufficiently confident of
this for clinical implementation requires robust quality
assurance techniques, phantoms, and the characterization of
the MRI distortions. The reported studies focused on
designing suitable phantoms for measuring geometric dis-
tortions or end-to-end testing the MR-only pathway,22-26
Table 3 Summary of the key results from the MR distortion quantification and phantom development studies
Author Year Phantom and software
Phantom Shape
(cm  cm  cm)
MR scanner and
magnet strength Other key information
Price
et al32
2015 Philips temporal GNL
phantom; in-house
3D distortion phantom;
in-house software
2D: 36  43  2
3D: 46.5  35  16.8
Philips Panorama, 1 T 1. Gradient nonlinearity distortions found to
be stable over 6-month period
2. Vendor 3D distortion corrections main-
tained <1 mm distortion up to 9.5 cm
from isocenter
3. Postprocessing corrected distortions <1
mm for large FoV up to 25 cm from
isocenter
4. Significant inherent gradient nonlinearity
distortions may be a specific feature of
open-bore MR scanners, rather than cy-
lindrical scanners, due to shorter gradient
coils
Sun
et al25
2015 Self-developed
pelvic-shape
phantoms and
software
25  40  26 Siemens Skyra, 3 T 1. Phantom internal details: spherical and
cylindrical inserts representing prostate,
rectum bladder, and femoral heads based
on average of 39 prostate patients or 11
plastic grid sheets
2. Maximum distortion across phantom with
3D correction found to be 1.7 mm (75%
quartile, 0.54 mm).
3. Phantom end to end testing found mean
dose difference of 1.1 cGy between CT
and MR
Walker et al24 2015 Self-developed large
FoV phantom
and software
Max: 50  50  51.3 Siemens Skyra, 3 T 1. Maximum 3D distortion correction
distortion was 4.08 mm for a 2-mm SE
sequence.
2. Within 152 mm of isocenter for 2 mm SE
with 3D distortion correction, distortion
 2 mm
3. For the continuous moving-table mode,
1.1 mm/s was found to have the least
distortion with a maximum of 4.4 mm
and a distance of 140 mm within which
the distortion was less than 2 mm.
Huang
7et al23
2016 Self-developed large
FoV phantom and
software
46.5  35  16.8 Siemens Skyra, 3 T Mean Bo distortion <1 mm found within a
radius of 15 cm from the isocenter
Torfeh
et al31
2016 GE large-FoV phantom
and in-house software
50  50  50 GE MR-Sim, 1.5 T 1. In-house software validated with a mean
distortion error of 0.15 mm
2. Mean Bo distortion both in-plane and
through plane found to be <2 mm within
a radius of 25 cm when manufacturer 2D
and 3D distortion applied as
recommended
3. Without distortion correction, the size of
distortions made use for radiation therapy
purposes unachievable
Gustafsson
et al27
2017 Spectronics large-FoV
GRADE phantom
and software
50.2  40.4  53.4 GE Discovery, 3 T 1. Mean and maximum distortions <0.5
mm and <12.6 mm, respectively
2. Maximum distortions: 0.43 mm at <100
mm, 0.82 mm at 100-150 mm, 1.85 mm
at 150-200 mm, and 7.9 at 200-250 mm,
increasing with radial distance from
isocenter
3. Structure deformation was minimal with
mean magnitude 0.01 mm for internal
structures and <0.33 mm for the full-
body contour; mean percentage dose
difference was 0.02%.
Kemppainen
et al19
2017 Large-FoV phantom
and software,
unknown origin
Minimum:
37.5  37.5  45.5
Philips Ingenia, 1.5 T 1. Mean system distortion of <1 mm
measured within all PTVs with mean
maximum distortion within patient body
contours of <2 mm
2. Effects of geometric distortion on dose
calculation accuracy found to be <0.2%
for all PTVs, with mean patient-induced
distortions <1 mm in all cases
(continued on next page)
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Table 3 (continued )
Author Year Phantom and software
Phantom Shape
(cm  cm  cm)
MR scanner and
magnet strength Other key information
Price et al22 2017 Self-developed
large-FoV phantom
in-house software
Maximum:
55  55  45
Philips Panorama, 1 T;
Philips Ingenia, 1.5 T;
Philips Ingenia, 3 T
1. Phantom modular to allow variation in
setup for different scanners
2. Setup reproducibility measured to be 0.1,
0, and e0.6 mm respectively in X, Y, and
Z directions with negligible rotations
3. Distortion <1 mm within 100 mm radi-
ally to isocenter
Tyagi
et al18
2017 X X Philips Ingenia, 3 T Mean patient-induced susceptibility geometric
distortion of e0.07 mm (range, e0.73 to
e0.56 mm) and e0.2 mm (range: e0.62 to
e0.35 mm) within the outer body and
prostate, respectively
Adjeiwaah
et al29
2018 Spectronics phantom
and software
35.1  47  45.1 GE Signa, 3 T 1. For sequences of bandwidths of 122, 244,
and 388 Hz, system distortions were
<3.19 mm, <2.52 mm, and <2.08 mm
within a radial distance of 25 cm from the
isocenter, and the patient-induced distor-
tions were <5.8 mm, <2.9 mm, and <1.5
mm, respectively
2. Dosimetric analysis found that a mean
dose difference of <0.5% was found be-
tween distorted and undistorted treatment
plans
3. Higher bandwidth sequences are recom-
mended to minimize distortion effects
Cunningham
et al26
2018 Self-developed male
pelvic-shape
phantom
23  38.1  Unknown Not applicable 1. External and internal organ shapes based
on data from 19 prostate cancer patients
2. Internal structure: pelvic bone anatomy,
prostate, urethra, and fillable bladder and
rectum
3. Modular changes are possible to accom-
modate dosimetry inserts or organ
changes
4. Phantom able to accurately and repro-
ducibly simulate rectum and bladder
filling and to dosimetrically verify treat-
ment plans, with an assessment plan
found to have a dose difference of 1.5%
between the calculated and measured
doses
Glide-Hurst
et al28
2018 X X Philips Panorama, 1 T;
Philips Achieva, 1.5 T;
Philips Ingenia, 3 T
1. Empty, partially full, and full bladder
states investigated over w45 minute
scanning session
2. Patient-induced susceptibility distortions
were small with <2% of prostate and
seminal vesicles voxels distorted by >0.5
mm and all-bladder voxels distorted by
<1 mm.
3. A significant change in rectal gas seen to
increase distortion
Wyatt et al30 2018 Spectronics Large
FoV GRADE
phantom and
software
50.2  40.4  53.4 Siemens Magnetom
Espree, 1.5 T; Siemens
Prisma, 3 T; GE Signa
PET-MR, 3 T
1. Bo distortion measurements for intra-
scanning and interscanning sessions were
repeatable
2. Mean range of measurement for all
scanners and sequences less than 1 mm,
maximum ranges 2.9 mm and 2.6 mm for
1.5-T and 3-T scanners
3. Phantom found to be relatively sensitive
to large set up errors w1 mm translation
or 1 degree of rotation
Abbreviation: 2DZ 2-dimensional; 3DZ 3-dimensional; FoVZ field of view; MRZ magnetic resonance; PTVZ planning target volume; SEZ
spin echo.
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the reproducibility of distortion measurements30 and pro-
vide information to aid distortion commissioning for an
MR-only pathway.Distortions within 1-T,22,28,32 1.5-T,19,22,28,30,31 and 3-T
scanners18,22-25,27,28,30 from a range of manufacturers,
including Siemens,23-25,30 Philips,18,19,22,28,32 and GE,27,31
were measured within a satisfactory range for MR-only
Table 4 Summary of the key results from the clinical validation of patient treatment positioning in MR-only workflow studies
Author Year
sCT
technique
No. of
Patients
DRR/
CBCT 2D method CBCT method
Inter/
Intraobserver
Korhonen
et al34
2015 Korhonen
et al39
DRR, 5;
CBCT, 5
DRR and
CBCT
Manual, bony
registration
Automatic
(bony and gray)
value, 3D and 6D
registration
DRR
interobserver: 10
Tyagi
et al18
2017 Philips
MR-CAT
DRR, 20;
CBCT, 5
DRR and
CBCT
Manual, fiducial
marker
registration
Manual, fiducial
marker
registration
X
Kemppainen
et al33
2018 Philips
MR-CAT
20 DRR Manual, bony
registration
X Interobserver, 5;
intraobserver, 3
Abbreviations: 2D Z 2-dimensional; 3D Z 3-dimensional; 6D Z 6 degrees of freedom; AP Z anterior-posterior; CBCT Z cone beam computed
tomography; CT Z computed tomography; DRR Z digitally reconstructed radiograph; LR Z left-right; MR Z magnetic resonance;
sCT Z synthetic computed tomography; SI Z superior-inferior.
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sented studies, Wyatt et al30 and Price et al32 suggested that
the majority of distortions measured as part of their studies
were larger than clinically acceptable for MR-only plan-
ning. However, both authors noted that their MR sequences
were not optimized for clinical use because their acquired
sequence bandwidths were insufficient to reduce distortion
to within acceptable levels, where a minimum suitable
bandwidth is considered to be 220 Hz/pixel at 1.5 T and 440
Hz/pixel at 3 T. This is a timely reminder that scanners and
clinically used scans require distortion characterization to
ensure they are suitable for use.
It is important that distortions be placed in context by
evaluating their effect on patient treatments. A number of
studies did this by assessing the effects of different dis-
tortions when applied to patient treatment plans, with
Kemppainen et al19 and Gustafsson et al27 assessing system
distortions; Tyagi et al,18 Kemppainen et al,19 and Glide-
Hurst28 assessing patient-induced susceptibility distor-
tions; and Adjeiwaah et al29 assessing both system and
patient-induced susceptibility distortions. These results
broadly showed that these distortions can be considered to
have negligible effects on the patient plan, although their
assessment and subsequent protocol optimization is vital.
This is particularly true when regarding patient-induced
distortions, which cannot be corrected systematically
because they vary between patients; however, these studies
provide confidence that their effects can be quantified ornegated for a range of scanners and magnet strengths.
Similar investigations should form part of any center’s
clinical implementation of MR-only planning to allow
local distortion effects to be quantified and assessed as
clinically significant or not. It is noted these studies were
undertaken with low patient numbers (20 or fewer), and in
none of the studies were distortions correlated with patient
size. Because distortions increase with distance from the
isocenter, their effects will increase with patient size.
Without information relating to patient sizes, it is not
possible to assess whether the true effect of the distortions
on larger patients has been quantified. Selection of a large
range of patient sizes and quantification of the impact of
distortion as a function of patient size potentially would be
of more value to a commissioning center than an attempt to
establish the “average” patient size.
It is also to the wider radiation therapy community’s
benefit that self-developed phantom designs be detailed in the
literature22-26 to allow centers to replicate these phantoms. It
was noticeable that for pelvic MR-only large-FoV distortion
measurements, these studies used only 2 commercially
available phantomsdthe Spectronics Medical’s GRADE27,30
and GE’s large-FoV phantoms31dwith the remaining studies
developing their own phantoms.22-26 However, it should be
noted that there are several other commercially available
phantoms that have not been reported here, including the
Quasar MRID 3D, CIRS large FoV, Phantomlab MagPhan
RT, and Philips MRI distortion phantoms. It is possible that
Table 4 Summary of the key results from the clinical validation of patient treatment positioning in MR-only workflow studies
(continued)
Other key information
CBCT (maximum difference) Gray value method sCT vs CTd2 mm (3D), and 1.7 mm, 1.1 (6D)
MR vs CTd4 mm (3D), and 3.5 mm, 1.6 (6D)
Bone method sCT vs CTd1.6 mm, and 1.3 (6D)
DRR Heterogeneous sCT vs CTdmanual registration errors were highest in the PA direction
with mean differences of e0.3  1 m and 0.3  1.7 mm for kV and MV acquired
positional images, respectively
CBCT (mean difference) sCT vs CT: <1  0.79 mm, <1  0.89 mm, <0.5  0.85 mm for LR, AP, and SI
directions, respectively
Other information Individual registration differences were observed up to 2 mm in some fractions with
larger variations in prostate rotation
DRR (mean difference) sCT vs CT: 0.3 mm, 0.3 mm, and 0.6 mm in the lateral, vertical and longitudinal
directions, respectively
DRR (mean difference) sCT vs CT: e0.5 mm, þ0.1 mm and þ0.1 mm in the vertical, longitudinal, and lateral
directions, respectively
Other information 1. Repeatability coefficients were 2.1 mm vs 2.6 mm, 1.4 mm vs 2.1 mm, and 1.2
mm vs 1.4 mm in vertical, longitudinal, and lateral directions between CT and
sCT, respectively
2. Significant increase in intraobserver variability found for vertical, longitudinal,
and lateral directions; however, magnitude was less than 0.5 mm in all directions
3. MRCAT has positive effect on total geometric accuracy compared with 2-mm
registration error of CT-MR pathway
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review because of the search criteria focusing on MR-only
clinical implementation pathways, rather than CT-MRI
pathways. As such, further comment on their potential
benefit in this context is not possible.
The anthropomorphic phantoms from Sun et al25 and
Cunningham et al26 are a beneficial development in phan-
tom design because they allow quantitative end-to-end
testing, including dose measurements within the phan-
toms. Of interest is the ability of one set of phantoms26 to
model physiologic changes in the bladder and rectum,
which will improve the commissioning process by allowing
the effects of patient anatomic changes to be assessed in a
quantitative and reproducible manner. Further development
of anthropomorphic phantoms could increase their use in
the quality assurance of MR-only planning as it develops as
a clinical technique.
For MR-only planning to be implemented, MR data are
required to be used for patient position verification pur-
poses before treatment. Publications relating to data
assessment as part of clinical implementation were limited,
however, with only Tyagi et al,18 Kemppainen et al,33 and
Korhonen et al34 assessing prostate patient treatment posi-
tioning accuracy. All 3 studies assessed DRR positioning,
with results showing broad agreement between the use of
planning CT and synthetic CTegenerated DRRs, providing
confidence that synthetic CTegenerated DRRs can produce
clinically acceptable results. Korhonen et al34 andKemppainen et al33 also investigated interobserver and
intraobserver variability for DRR registrations and found it
to be clinically insignificant.
Three-dimensional CBCTebased patient treatment
positioning was investigated using manual fiducial marker
registration18 and the automatic bone and gray-value
registration methods of Elekta’s XVI system.34 Synthetic
CTeto-CBCT registrations were comparable to planning
CT-to-CBCT registrations (mean differences <1 mm),
indicating that synthetic CT data sets can replace CT data
sets for manual or automatic registrations and for patient
treatment positioning. Tyagi et al18 also noted that, anec-
dotally, clinicians were happy with the delineations of
bladder and rectum on the synthetic CT. It is interesting that
the synthetic CTeto-CT results varied between Korhonen
et al34 and Tyagi et al.18 This could be influenced by a
number of factors, including the difference in matching
technique (automatic vs manual) or the inclusion of a pa-
tient mold within Tyagi’s study to improve setup
reproducibility.
MR-to-CBCT registrations were also assessed by
Korhonen et al,34 but they did not replicate the same level
of similarity to planning CT-to-CBCT registrations as
synthetic CTeto-CBCT registrations. This result is under-
standable because XVI uses a chamfer matching algorithm
and is optimized for registering data sets of the same mo-
dality (ie, CT to CBCT), and registrations could improve if
more suitable mutual information algorithms were used. It
Table 5 Summary of the key results from the MR-only commissioning processes studies
Author Year
No. of
patients
in study* Other key information
Kapanen
et al35
2013 X Proposed calibration and testing procedures for verification of the treatment isocenter position,
geometric accuracy, and other basic QA with an ACR phantom
Korsholm
et al37
2014 21 A statistical model approach to assessing the accuracy of sCT calculation was used where the
criteria of accuracy was considered to be 95% of patients having an uncertainty in dose
calculation within the PTV within 2% of the CT dose
Maspero
et al21
2017 14 For electron density conversion, sCT generation, and interscan difference, average dose difference
in the CTV of 0.7%  0.2%, 0.16%  0.13%, and 0.01%  0.35% and in the whole body of
0.1%  0.03%, e0.03%  0.02%, and 0  0.06% were found, respectively
Kerkmeijer
et al15
2018 X Recommended requirements for MR-only radiation therapy clinical implementation including
geometric accuracy, treatment position MR acquisition, sCT generation, MRI-based OAR
delineation, and protocol optimization and MRI-based treatment position verification
Kim et al36 2018 X 1. Many processes and therefore failure modes are shared between CT-MR and MR-only
workflows with the highest failure modes related to changes in target location due to inter-
nal anatomy changes, in these cases current mitigation processes were still valid
2. The highest risk failure modes for the MR-only workflow alone related to the sCT generation
process, including: inaccuracies in target delineation on MR images, insufficient management
of patient- and system-level distortions and inaccurate bone volumes
3. Mitigation strategies for failures include sufficient staff training and a robust quality-control
and quality-assurance program
Palmer et al38 2018 10 1. The CBCT system was stable over time in HU (standard deviation <40 HU) and the variation
in HU between CT and CBCT was found to be minimal (<60 HU)
2. A comparison of the dose distributions between sCT and CT compared with sCT and CBCT
found mean dose differences for all metrics of 1%
3. The CBCT system can be considered to be similar to a CT system and can be used as a
clinically feasible QA procedure
Abbreviations: ACR Z American College of Radiology; CBCT Z cone beam CT; CT Z computed tomography; HU Z Hounsfield units; MR Z
magnetic resonance; MRI Z magnetic resonance imaging; PTV Z planning target volume; QA Z quality assurance; sCT Z synthetic CT.
* ”No. patients in Study” refers to the total number of patients recruited for the MR-only investigations.
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and that further commercial support and investment in this
field is required. In addition, it is important to note that
although differences are seen between CT and MR regis-
trations, from the data shown, neither CT nor MR can be
determined as more accurate because there is no ground
truth for comparison. It can only be determined that the
registrations produce different results. To resolve which
modality is more accurate, manual landmark evaluation can
be used for an initial comparison, and a future potential
solution would be to use an anthropomorphic phantom that
could provide the required ground truth information. It can
be hypothesized that it would be best to register MR to
CBCT, rather than synthetic CT to CBCT, because this
would mean that real rather than synthesized data were
being used, thus theoretically improving the registration
accuracy. These findings suggest that MR-only pathways
exist that allow reproducible patient positioning verification
to be completed. In addition, these studies provide a suit-
able methodology for a center looking to implement MR-
only planning with respect to the assessment of patient
treatment positioning accuracy and reproducibility.
A wide variety of processes and experiences relating to
commissioning an MR-only pathway were reported forprostate treatments. The experiences of Kerkmeijer et al15
and Kapanen et al35 in terms of workflow, equipment,
and commissioning requirements provide substantial
amounts of information, which is particularly beneficial
because these processes, within this early phase of clinical
implementation, are not well established. It is a challenging
process to determine the commissioning and routine
workflow to ensure optimal performance and the highest
quality of patient care; therefore, more publications de-
tailing individual centers’ experiences, such as these, would
be welcome until this technique is more firmly embedded in
routine clinical practice or guidance documents are pub-
lished. The information provided within the work of Kim
et al36 provides useful tools for identifying risks and
highlights many risks that will be shared among all MR-
only pathways; it also suggests mitigation strategies to
lessen their influence. That the greatest source of risk is the
synthetic CT generation process is not a surprising result;
however, the strength of this methodology is that it provides
an overall framework for assessing, comparing, and mini-
mizing risks. This methodology also allows the user to have
confidence that their MR-only pathway is optimized to
protect from errors as much as is reasonably practicable. In
addition, as a process, it can be repeated over time to
Volume 105  Number 3  2019 MR-only pelvic implementation systematic review 491reassess and fine-tune the pathway continually; it is also
applicable to any future MR-only treatment sites in addition
to prostate cancer, which was presented here.
The quantification of the accuracy of a center’s local
synthetic CT generation technique is a key stage of
commissioning an MR-only pathway, and the studies by
Maspero et al21 and Korsholm et al37 provide differing
methods of undertaking this. It is interesting to see that
Maspero et al21 found that electron density conversion
(from CT scanegenerated Hounsfield units to electron
density via an election density plotted curve) was the
greatest confounding factor, followed by synthetic CT
generation (the assigning of Hounsfield units to MR scan
voxels to produce the synthetic CT). Interscan differences
(setup and positioning differences between CT and MRI
scans, MR geometric inaccuracy, and CT-MRI registration
errors as required for comparison) produced almost a
negligible difference in result. This finding suggests that the
commissioning process should also focus on appropriate
electron density curve calibration as a key part of the
commissioning process.
Palmer et al38 present a method of validating synthetic
CT generations using collected patient CBCT data and
provide a tool by which commissioning centers can ensure
further confidence over the accuracy of their treatment
planning pathway. As previously discussed by Kim et al,36
the generation of synthetic CTs is a major risk in the MR-
only pathway, and the challenge of ensuring robust patient
treatment on an individual basis is nontrivial. The method
of Palmer et al would directly allow a gross error check on
the treatment plan, which could highlight potential issues at
the beginning of a patient’s treatment. Palmer et al38 noted,
however, that further analysis of this technique would be
beneficial, as only simple errors were assessed within the
validation presented; as a consequence, its sensitivity to
less-noticeable errors is uncertain.
The studies identified here are a significant step toward
widespread pelvic MR-only clinical implementation; how-
ever, further attention is required in several areas. As dis-
cussed previously, the translation of this technique to other
clinical pelvic sites is a significant challenge that should not
be underestimated. Several studies reported issues associ-
ated with processing data within MR-only pathways. These
issues may be due to a lack of support for the MR-only
workflow by radiation therapy vendors. Clinical treatment
planning software and further collaboration, investment, or
support from commercial companies would be beneficial.
Unseen in the literature was a long timescale (1 year) Bo
distortion evaluation study focusing on its effects on an
MR-only pathway. Long timescale changes in Bo distortion
could have a significant influence on resultant MRI geo-
metric accuracy, which would require correction to prevent
the translation of errors into the planning process. Such a
study would demonstrate the reliability and reproducibility
of scanner Bo distortion over time and therefore provide
evidence for distortion quality assurance frequency rec-
ommendations. Patient treatment positioning verificationwithin clinical implementation was addressed in only 3
studies. Although the results presented were encouraging
and suggested that MR-only techniques can accurately be
used for patient treatment positioning, there is plenty of
evidence yet to be gathered. All these studies involved
small cohorts of patients and used the synthetic CT gen-
eration method of the Philips prostate MRCAT11 or
similar,39 which are not comparable to all methods of
synthetic CT generation. In addition, the majority of results
were collected with manual registration techniques,
whereas it is common in the clinic to use a manufacturer’s
automated or semiautomated technique. The effects
different clinical equipment and techniques, in larger pa-
tient cohorts, need to be investigated fully.
Despite the variety of publications related to MR-only
commissioning and individual centers experiences, the ra-
diation therapy community is so varied in term of equip-
ment, resources, and technique that there is significant
scope for further experience to be reported in the literature
and consensus guidelines to be produced by early adopters
and national bodies. There is also a substantial need for
more studies to begin providing evidence of the benefit of
using MR-only planning, such as improved patient out-
comes or treatment pathway improvements.
Conclusion
MR-only planning has been clinically implemented for the
treatment of prostate cancer; however, further research is
required to develop MR-only planning for other pelvic
sites. In particular, the accuracy of synthetic CT generation
models for female anatomy requires further reporting
within the literature. MR scanner distortions are no longer a
barrier to MR-only planning, although they must be
managed appropriately, whereas MR data acquisition and
synthetic CT generation for prostate treatments have been
shown to be sufficiently accurate for clinical use. The
clinical implementation of MR-only patient treatment
positioning verification remains underreported in the liter-
ature and requires substantial investigation to allow its
widespread use. The range of investigations reported here
are a suitable starting point for radiation therapy centers
aiming to clinically implement MR-only planning; how-
ever, further evidence and regulation is required, including
the publication of consensus guidelines from early adopters
and governing bodies.
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